At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ACXP Acurx Pharmaceuticals, LLC*
Not Yet Opened 07-21 16:00:00 EDT
1.52
-0.03
-1.94%
盘后1.51
-0.01-0.66%
19:34 EDT
High1.58Low1.47Vol73.13K
Open1.58D1 Closing1.55Amplitude7.10%
Mkt Cap6.50MTradable Cap6.34MTotal Shares4.28M
T/O110.12KT/O Rate1.75%Tradable Shares4.17M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Acurx Launches Pilot Trial of Ibezapolstat in Multiply Recurrent C. Difficile Infection
Reuters  ·  07-14
Acurx Launches Pilot Trial of Ibezapolstat in Multiply Recurrent C. Difficile Infection
Acurx Pharmaceuticals Posts Presentation on Ibezapolstat Microbiome Restoration Potential in Recurrent C. Difficile Infection
Reuters  ·  07-13
Acurx Pharmaceuticals Posts Presentation on Ibezapolstat Microbiome Restoration Potential in Recurrent C. Difficile Infection
Acurx Pharmaceuticals to Discuss Q2 Financial Results on Conference Call
Reuters  ·  07-08
Acurx Pharmaceuticals to Discuss Q2 Financial Results on Conference Call
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
THOMSON REUTERS  ·  07-08
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
Acurx says lead antibiotic ibezapolstat is ready to enter pivotal Phase 3 trials for C. difficile infection
Reuters  ·  06-16
Acurx says lead antibiotic ibezapolstat is ready to enter pivotal Phase 3 trials for C. difficile infection
Acurx Pharmaceuticals Announces Presentation of Results From Leiden University Medical Center Public-Private Partnership for Its DNA Pol Iiic Inhibitors at the Leiden Early Drug Discovery & Development (Led3) Scientific Conference
THOMSON REUTERS  ·  06-16
Acurx Pharmaceuticals Announces Presentation of Results From Leiden University Medical Center Public-Private Partnership for Its DNA Pol Iiic Inhibitors at the Leiden Early Drug Discovery & Development (Led3) Scientific Conference
Analysts Conflicted on These Healthcare Names: Altimmune (ALT) and Acurx Pharmaceuticals (ACXP)
TIPRANKS  ·  05-14
Analysts Conflicted on These Healthcare Names: Altimmune (ALT) and Acurx Pharmaceuticals (ACXP)
Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE)
TIPRANKS  ·  05-13
Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE)
Acurx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-12
Acurx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Acurx Pharmaceuticals Q1 EPS USD -0.62
THOMSON REUTERS  ·  05-12
Acurx Pharmaceuticals Q1 EPS USD -0.62
Acurx Q1 net loss narrows 22% to $1.68 million
Reuters  ·  05-12
Acurx Q1 net loss narrows 22% to $1.68 million
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  05-11
Calendar of U.S. Earnings Expected in the Week Ahead
Acurx Pharmaceuticals Inc expected to post a loss of 63 cents a share - Earnings Preview
Reuters  ·  05-08
Acurx Pharmaceuticals Inc expected to post a loss of 63 cents a share - Earnings Preview
Acurx DNA pol IIIC inhibitors spare gut microbiome in MRSA mouse study, poster shows
Reuters  ·  05-04
Acurx DNA pol IIIC inhibitors spare gut microbiome in MRSA mouse study, poster shows
Acurx CEO to join Alliance Global Partners Healthcare Company Showcase fireside chat
Reuters  ·  04-29
Acurx CEO to join Alliance Global Partners Healthcare Company Showcase fireside chat
BRIEF-Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Reuters  ·  04-20
BRIEF-Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
THOMSON REUTERS  ·  04-20
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
BRIEF-Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Reuters  ·  04-17
BRIEF-Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx announces $7.1M registered direct offering priced at-the-market
TIPRANKS  ·  04-16
Acurx announces $7.1M registered direct offering priced at-the-market
Acurx prices $2.5 million registered direct offering at $3.03 per share
Reuters  ·  04-16
Acurx prices $2.5 million registered direct offering at $3.03 per share

Introduction

Company Name.
Acurx Pharmaceuticals, LLC*
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Issue price:
--